Tesamorelin vs CJC-1295: FDA vs Research GHRH

Tesamorelin is a synthetic GHRH analog composed of 44 amino acids with a trans-3-hexenoic acid modification at the N-terminus. It is the active ingredient in Egrifta SV, manufactured by Theratechnologies and FDA-approved in 2010 for reduction of excess visceral abdominal fat in HIV-infected patients with lipodystrophy.

Its half-life is 26-38 minutes. Daily subcutaneous injection at 2 mg produces a physiological GH pulse that clears within hours. The short half-life produces pulsatile GH release that resolves within hours, similar to the body's natural GHRH signaling pattern.

Tesamorelin is the only GHRH analog to have completed Phase III randomized, double-blind, placebo-controlled trials published in top-tier journals. The Falutz 2007 NEJM study and the Stanley 2014 JAMA study represent the gold standard of clinical evidence in this class (Falutz et al., NEJM, 2007).

CJC-1295 is a synthetic analog of GHRH (growth hormone releasing hormone), specifically a modified version of GRF(1-29). It exists in two distinct formulations with very different pharmacokinetic profiles. Developed by ConjuChem Biotechnologies (now dissolved), it never progressed past Phase I/II trials.

The evidence gap between tesamorelin and CJC-1295 is the single most important factor in this comparison. The gap is wide.

Tesamorelin is the only GHRH analog with published data on visceral fat reduction. The results are substantial: 18% VAT reduction in Phase III trials, 69% responder rate, and improvements in hepatic fat content.

CJC-1295 has zero published studies on visceral fat. The assumption that it reduces abdominal fat is extrapolated from its GH-elevating properties: elevated GH promotes lipolysis, and elevated IGF-1 shifts partitioning toward lean tissue. This is reasonable physiology but not clinical proof.

For anyone whose primary goal is visceral fat reduction with documented evidence, tesamorelin is the clear choice. For a complete dosing guide, see our tesamorelin dosage for fat loss article.

The Stanley 2014 JAMA study documented a benefit beyond VAT reduction: tesamorelin reduced liver fat in subjects with HIV-associated lipodystrophy. This finding has generated interest in tesamorelin for non-HIV populations with non-alcoholic fatty liver disease (NAFLD).

Triglyceride reduction of approximately 50 mg/dL was documented in the Falutz NEJM study. Adiponectin levels improved in responders, suggesting enhanced insulin sensitivity in the metabolic pathway (Fourman et al., 2012).

CJC-1295 has no liver-specific data. GH elevation generally promotes hepatic lipolysis, but whether CJC-1295 produces clinically meaningful liver fat reduction has not been tested. The absence of data is not evidence of absence, but for patients with NAFLD concerns, tesamorelin has a published track record.

Tesamorelin requires daily subcutaneous injections at 2 mg. The injection is straightforward: reconstitute the vial, draw 2 mg, inject subcutaneously in the abdomen. Rotate sites daily.

CJC-1295 with DAC requires only 1-2 injections per week at 1-2 mg per dose. This is a meaningful convenience advantage for users who dislike frequent injections.

CJC-1295 without DAC requires 2-3 injections daily at 100-200 mcg per injection, typically paired with ipamorelin. This is the least convenient option.

For weekly injection convenience, CJC-1295 with DAC is the winner. For evidence-backed daily dosing with a proven outcome, tesamorelin is the standard.

Both tesamorelin and CJC-1295 are generally well tolerated, but tesamorelin has far more comprehensive safety data.

CJC-1295 with DAC causes more water retention and tingling than tesamorelin, likely because its 6-8-day half-life maintains continuous GH elevation. Tesamorelin's short half-life produces a GH pulse that clears within hours, resulting in less sustained fluid retention.

Both compounds share the GH-class risks of insulin sensitivity changes and theoretical IGF-1/cancer concerns with long-term use. See our CJC-1295/ipamorelin side effects guide for detailed management protocols.

Cost is a major factor in this decision, and the range is wide.

Brand Egrifta SV is prohibitively expensive for most non-HIV patients. Compounded tesamorelin costs roughly the same as CJC-1295. The cost advantage of CJC-1295 disappears when using the no-DAC version with ipamorelin, which adds $100-200/month for the combination.

For budget-conscious users, the choice between compounded tesamorelin and CJC-1295 is roughly equivalent in price. The decision then shifts to evidence strength (tesamorelin) versus convenience (CJC-1295 DAC weekly dosing).

Tesamorelin (Egrifta SV) holds FDA approval under NDA 022505, specifically for reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. All other use is off-label but legal with a prescription. Physicians can prescribe tesamorelin off-label for non-HIV patients with visceral adiposity.

CJC-1295 has never been submitted for FDA approval. It is classified as a research chemical. Access is through compounding pharmacies (with prescription) or research chemical suppliers.

Both compounds are available through compounding pharmacies with a valid prescription. The FDA's 2024 PCAC (Pharmacy Compounding Advisory Committee) proceedings may affect future compounding availability for both. For CJC-1295 context, see our CJC-1295 vs sermorelin comparison.

The decision depends on your primary goal, comfort with evidence levels, and access.

Combining tesamorelin with CJC-1295 is generally not recommended. Both are GHRH receptor agonists. Stacking two compounds that hit the same receptor provides diminishing returns rather than synergy.

Some clinics use tesamorelin blended with ipamorelin (a ghrelin receptor agonist) for GHRH-GHRP synergy. This is pharmacologically sound: two different receptor pathways create a larger GH response than either alone.

Cycling between tesamorelin and CJC-1295 is another option. Use tesamorelin for a 3-6 month fat loss phase, then transition to CJC-1295/ipamorelin for maintenance. This leverages tesamorelin's proven VAT reduction during the active fat loss window and CJC-1295's weekly convenience during maintenance. For stacking protocols, see our peptide stacking guide.

Tesamorelin is contraindicated in patients with active malignancy, as GH promotion may stimulate tumor growth. It is also contraindicated in pregnancy (Category X) due to potential fetal harm.

CJC-1295 has no FDA-approved labeling and therefore no formal contraindications. Apply the same precautions as any GH-elevating compound: avoid use with active cancer, monitor IGF-1 levels, and check fasting glucose periodically.

Both compounds should be discontinued if IGF-1 exceeds the upper reference range, fasting glucose rises above 126 mg/dL, or severe edema develops. Consult a physician before starting either compound. For related comparisons, see our best peptides for weight loss guide.